Conference Reports for NATAP

Back

HIV Glasgow 2026 8-11 November     Higher Persistence on Twice-yearly Lenacapavir Versus Daily F/TDF for PrEP in the UK and France in the PURPOSE 5 Study - (11/08/26)   Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow - (11/04/26)